重症虚血肢(Critical Limb Ischemia):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Critical Limb Ischemia - Pipeline Review, H2 2014
◆商品コード:GMDHC5799IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月30日
◆ページ数:124
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における重症虚血肢(Critical Limb Ischemia)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・重症虚血肢(Critical Limb Ischemia)の概要
・重症虚血肢(Critical Limb Ischemia)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・重症虚血肢(Critical Limb Ischemia)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・重症虚血肢(Critical Limb Ischemia)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・重症虚血肢(Critical Limb Ischemia)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Critical Limb Ischemia – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Critical Limb Ischemia – Pipeline Review, H2 2014’, provides an overview of the Critical Limb Ischemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Critical Limb Ischemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Critical Limb Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Critical Limb Ischemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Critical Limb Ischemia Overview 9
Therapeutics Development 10
Pipeline Products for Critical Limb Ischemia – Overview 10
Pipeline Products for Critical Limb Ischemia – Comparative Analysis 11
Critical Limb Ischemia – Therapeutics under Development by Companies 12
Critical Limb Ischemia – Therapeutics under Investigation by Universities/Institutes 14
Critical Limb Ischemia – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Critical Limb Ischemia – Products under Development by Companies 19
Critical Limb Ischemia – Products under Investigation by Universities/Institutes 20
Critical Limb Ischemia – Companies Involved in Therapeutics Development 21
Aastrom Biosciences, Inc. 21
AnGes MG, Inc. 22
Apceth GmbH & Co. KG 23
Athersys, Inc. 24
Hemostemix Ltd 25
Human Stem Cells Institute 26
Juventas Therapeutics, Inc. 27
Kasiak Research Pvt. Ltd. 28
Multi Gene Vascular Systems Ltd 29
NeoStem, Inc. 30
Nuo Therapeutics, Inc. 31
Pharmicell Co., Ltd. 32
Pluristem Therapeutics Inc. 33
ReNeuron Group plc 34
Stempeutics Research Private Limited 35
TikoMed AB 36
ViroMed Co., Ltd. 37
Critical Limb Ischemia – Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
ACP-01 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ALD-301 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Alecmestencel-T – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
AMR-001 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ASCT-01 – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
beperminogene perplasmid – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Cell Therapy for Critical Limb Ischemia – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Cellgram for Severe Lower Limb Ischemia – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Diseases – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ixmyelocel-T – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
JVS-100 – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
MultiGeneAngio – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
MultiStem – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Protein for Myocardial Infarction and Critical Limb Ischemia – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Recombinant Protein for Critical Limb Ischemia – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Refacell-CLI – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
ReN-009 – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Stem Cell Therapy for Cardiovascular Diseases – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Stem Cell Therapy for Critical Limb Ischemia – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Stem Cell Therapy for Critical Limb Ischemia – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Stem Cell Therapy for Critical Limb Ischemia – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Stempeucel – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Stromal Cell Therapy for Critical Limb Ischemia – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
TM-700 – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
VM-202 – Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Critical Limb Ischemia – Recent Pipeline Updates 88
Critical Limb Ischemia – Dormant Projects 114
Critical Limb Ischemia – Discontinued Products 115
Critical Limb Ischemia – Product Development Milestones 116
Featured News & Press Releases 116
Nov 18, 2014: Juventas Therapeutics Presents Phase II Data at AHA Scientific Sessions That Shows JVS-100 is Safe, Potentially Effective in Patients with Critical Limb Ischemia 116
Oct 05, 2014: AnGes Starts Global Phase III Clinical Trials of Collategene for Critical Limb Ischemia 117
Jun 25, 2014: Hemostemix Advances Clinical Trial Preparation 117
Apr 22, 2014: Hemostemix Announces its Second US Patent 118
Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia 118
Apr 10, 2013: Athersys Announces Publication Of Study Results Demonstrating Relevance Of MultiStem For Autoimmune Disease, Transplantation And Vascular Disease 119
Mar 27, 2013: Aastrom Biosciences Announces Strategic Change In R&D Programs To Focus On Dilated Cardiomyopathy And Other Rare Disease Indications 120
Mar 26, 2013: ReNeuron Receives Regulatory And Ethical Approvals To Commence Clinical Trial In UK With Stem Cell Therapy Candidate For Critical Limb Ischaemia 120
Mar 11, 2013: ReNeuron Wins £0.4m Grant From UK Biomedical Catalyst To Pursue Further Development Of ReN009 Stem Cell Therapy Candidate 121
Mar 04, 2013: AnGes Group Receives FDA Approval For Revised Special Protocol Assessment For Collategene Phase III Clinical Trial 122
Appendix 123
Methodology 123
Coverage 123
Secondary Research 123
Primary Research 123
Expert Panel Validation 123
Contact Us 124
Disclaimer 124

[List of Tables]
Number of Products under Development for Critical Limb Ischemia, H2 2014 10
Number of Products under Development for Critical Limb Ischemia - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Comparative Analysis by Unknown Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Investigation by Universities/Institutes, H2 2014 20
Critical Limb Ischemia - Pipeline by Aastrom Biosciences, Inc., H2 2014 21
Critical Limb Ischemia - Pipeline by AnGes MG, Inc., H2 2014 22
Critical Limb Ischemia - Pipeline by Apceth GmbH & Co. KG, H2 2014 23
Critical Limb Ischemia - Pipeline by Athersys, Inc., H2 2014 24
Critical Limb Ischemia - Pipeline by Hemostemix Ltd, H2 2014 25
Critical Limb Ischemia - Pipeline by Human Stem Cells Institute, H2 2014 26
Critical Limb Ischemia - Pipeline by Juventas Therapeutics, Inc., H2 2014 27
Critical Limb Ischemia - Pipeline by Kasiak Research Pvt. Ltd., H2 2014 28
Critical Limb Ischemia - Pipeline by Multi Gene Vascular Systems Ltd, H2 2014 29
Critical Limb Ischemia - Pipeline by NeoStem, Inc., H2 2014 30
Critical Limb Ischemia - Pipeline by Nuo Therapeutics, Inc., H2 2014 31
Critical Limb Ischemia - Pipeline by Pharmicell Co., Ltd., H2 2014 32
Critical Limb Ischemia - Pipeline by Pluristem Therapeutics Inc., H2 2014 33
Critical Limb Ischemia - Pipeline by ReNeuron Group plc, H2 2014 34
Critical Limb Ischemia - Pipeline by Stempeutics Research Private Limited, H2 2014 35
Critical Limb Ischemia - Pipeline by TikoMed AB, H2 2014 36
Critical Limb Ischemia - Pipeline by ViroMed Co., Ltd., H2 2014 37
Assessment by Monotherapy Products, H2 2014 38
Number of Products by Stage and Target, H2 2014 40
Number of Products by Stage and Mechanism of Action, H2 2014 42
Number of Products by Stage and Route of Administration, H2 2014 44
Number of Products by Stage and Molecule Type, H2 2014 46
Critical Limb Ischemia Therapeutics - Recent Pipeline Updates, H2 2014 88
Critical Limb Ischemia - Dormant Projects, H2 2014 114
Critical Limb Ischemia - Discontinued Products, H2 2014 115

[List of Figures]
Number of Products under Development for Critical Limb Ischemia, H2 2014 10
Number of Products under Development for Critical Limb Ischemia - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Products, H2 2014 17
Assessment by Monotherapy Products, H2 2014 38
Number of Products by Top 10 Targets, H2 2014 39
Number of Products by Stage and Top 10 Targets, H2 2014 40
Number of Products by Top 10 Mechanism of Actions, H2 2014 41
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 42
Number of Products by Top 10 Routes of Administration, H2 2014 43
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 44
Number of Products by Top 10 Molecule Types, H2 2014 45
Number of Products by Stage and Top 10 Molecule Types, H2 2014 46

【掲載企業】

Aastrom Biosciences, Inc.
AnGes MG, Inc.
Apceth GmbH & Co. KG
Athersys, Inc.
Hemostemix Ltd
Human Stem Cells Institute
Juventas Therapeutics, Inc.
Kasiak Research Pvt. Ltd.
Multi Gene Vascular Systems Ltd
NeoStem, Inc.
Nuo Therapeutics, Inc.
Pharmicell Co., Ltd.
Pluristem Therapeutics Inc.
ReNeuron Group plc
Stempeutics Research Private Limited
TikoMed AB
ViroMed Co., Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[重症虚血肢(Critical Limb Ischemia):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆